TABLE 3.
Multivariate regression analysis – Cox proportional hazards models for progression‐free and overall survival in MZL
| Progression‐free survival | |||
|---|---|---|---|
| Variable | Patients n (%) | HR (95% CI) | p‐value |
| Overall MZL (n = 175) | |||
| Age (10‐years increments) | ‐ | 1.64 (1.23–2.20) | <0.001* |
| B symptoms | |||
| Present | 50 (28.6%) | Reference | ‐ |
| Not present | 112 (64.0%) | 0.60 (0.34–1.07) | 0.083 |
| Unknown | 13 (7.4%) | 0.19 (0.03–1.44) | 0.109 |
| MALT MZL (n = 58) | |||
| B symptoms | |||
| Present | 9 (15.5%) | Reference | ‐ |
| Not present | 42 (72.4%) | 0.29 (0.10–0.88) | 0.029* |
| Unknown | 7 (12.1%) | 0.00 (0.00–NA) | 0.993 |
| Non‐MALT MZL (n = 117) | |||
| Age (10‐years increments) | ‐ | 1.90 (1.33–2.72) | <0.001* |
| B symptoms | |||
| Present | 41 (35.0%) | Reference | |
| Not present | 70 (59.8%) | 0.57 (0.29–1.14) | 0.113 |
| Unknown | 6 (5.1%) | 0.22 (0.03–1.77) | 0.155 |
| Increased LDH | |||
| Yes | 38 (32.5%) | Reference | ‐ |
| No | 75 (64.1%) | 2.36 (1.03–5.38) | 0.042* |
| Unknown | 4 (3.4%) | 0.00 (0.00–NA) | 0.992 |
| Spleen involvement | |||
| Yes | 31 (26.5%) | Reference | ‐ |
| No | 86 (73.5%) | 0.41 (0.17–1.00) | 0.051 |
| Bone marrow involvement | |||
| Yes | 50 (42.7%) | Reference | ‐ |
| No | 67 (57.3%) | 2.65 (1.14–6.14) | 0.023* |
| Overall survival | |||
|---|---|---|---|
| Variable | Patients n (%) | HR (95% CI) | p ‐value |
| Overall MZL (n = 175) | |||
| Age (10‐years increments) | ‐ | 1.99 (1.38–2.85) | <0.001* |
| MALT MZL (n = 58) | |||
| Age (10‐years increments) | ‐ | 2.44 (1.17–5.08) | 0.017* |
| Bone marrow involvement | |||
| Yes | 8 (13.8%) | Reference | ‐ |
| No | 50 (86.2%) | 0.33 (0.08–1.31) | 0.115 |
| Non‐MALT MZL (n = 117) | |||
| Age (10‐years increments) | ‐ | 1.94 (1.28–2.96) | 0.002* |
| Increased LDH | |||
| Yes | 38 (32.5%) | Reference | ‐ |
| No | 75 (64.1%) | 2.33 (0.91–5.96) | 0.077 |
| Unknown | 4 (3.4%) | 0.00 (0.00–NA) | 0.992 |
| Spleen involvement | |||
| Yes | 31 (26.5%) | Reference | ‐ |
| No | 86 (73.5%) | 0.37 (0.13–1.02) | 0.055 |
| Bone marrow involvement | |||
| Yes | 50 (42.7%) | Reference | ‐ |
| No | 67 (57.3%) | 2.16 (0.83–5.62) | 0.114 |
Note: Backwards selection by minimizing Akaike information criterion (AIC) was chosen for variable selection. Models fitting best to the data have been selected and are presented here. Some percentages might not add up to 100% due to rounding.
Abbreviations: CI, confidence interval; HR, hazard ratio; y, year; LDH, lactate dehydrogenase; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma; NA, not applicable; OS, overall survival; PFS, progression‐free survival.
*Significant results (p < 0.05).